While immune checkpoint inhibitors targeting the PD1/PDL1 and CTLA-4 axes have revolutionized cancer treatment, novel drugs are needed to overcome the limitations of current adaptive ICI-based immunotherapies, including insufficient tumor antigens and poor antigen presentation. The gene discussed is CTLA4; the disease is neoplasm.